Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Carmen Vroonen
VP IR Senior Director Communications
+1 781 460 1784 +32 473 824 874
Director IR
+32 485 19 14 15 +31 6 53 591 999
ir@glpg.com communications@glpg.com
1 Belgian Act of
Attachment
- PDF version
© OMX, source